Impact of raw & starting materials on the manufacture and regulation of gene & cell therapies

In by

Spotlight Article


Cell & Gene Therapy Raw Materials: Getting it Right from the Start

Richard A Dennett, Valérie Pimpaneau and François Gianelli

Understanding the definition of raw and starting materials and the impact this has on the regulation and commercialization of your gene and
cell therapies is essential. To help shed light on this critical topic, Cell and Gene Therapy Insights spoke with members of the CMC team (Richard Dennett, Valérie Pimpaneau and François Gianelli) at Voisin Consulting Life Sciences who partner with Biotech, Pharma and Medtech manufacturers to develop, register and launch innovative products in North American and European markets.

DOI: 10.18609/cgti.2017.031
Citation: Cell Gene Therapy Insights 2017; 3(3), 189-195.
Open access

This content is restricted to registered users. Click here to Register or Login here.